CA2818990C - Designed repeat proteins binding to serum albumin - Google Patents
Designed repeat proteins binding to serum albumin Download PDFInfo
- Publication number
- CA2818990C CA2818990C CA2818990A CA2818990A CA2818990C CA 2818990 C CA2818990 C CA 2818990C CA 2818990 A CA2818990 A CA 2818990A CA 2818990 A CA2818990 A CA 2818990A CA 2818990 C CA2818990 C CA 2818990C
- Authority
- CA
- Canada
- Prior art keywords
- proteins
- serum albumin
- repeat proteins
- binding
- designed repeat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10192711.9 | 2010-11-26 | ||
| EP10192711 | 2010-11-26 | ||
| PCT/EP2011/071083 WO2012069654A1 (en) | 2010-11-26 | 2011-11-25 | Designed repeat proteins binding to serum albumin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2818990A1 CA2818990A1 (en) | 2012-05-31 |
| CA2818990C true CA2818990C (en) | 2021-06-15 |
Family
ID=43858162
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2818990A Active CA2818990C (en) | 2010-11-26 | 2011-11-25 | Designed repeat proteins binding to serum albumin |
| CA2818969A Active CA2818969C (en) | 2010-11-26 | 2011-11-25 | Improved n-terminal capping modules for designed ankyrin repeat proteins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2818969A Active CA2818969C (en) | 2010-11-26 | 2011-11-25 | Improved n-terminal capping modules for designed ankyrin repeat proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9284361B2 (enExample) |
| EP (3) | EP2643348B1 (enExample) |
| JP (3) | JP6173216B2 (enExample) |
| KR (3) | KR20140032356A (enExample) |
| CN (3) | CN103403024B (enExample) |
| AU (2) | AU2011333665B2 (enExample) |
| BR (3) | BR112013013043A2 (enExample) |
| CA (2) | CA2818990C (enExample) |
| DK (1) | DK2643349T3 (enExample) |
| ES (2) | ES2758352T3 (enExample) |
| PL (1) | PL2643349T3 (enExample) |
| RU (2) | RU2636552C2 (enExample) |
| WO (2) | WO2012069654A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| DK2643349T3 (da) | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| PT2846836T (pt) | 2012-05-07 | 2019-10-29 | Allergan Inc | Método de tratamento de dmi em doentes refratários à terapia anti-vegf |
| WO2014001442A1 (en) * | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2906591A1 (en) * | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| CN105143270B (zh) * | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| KR20150097304A (ko) | 2014-02-18 | 2015-08-26 | 삼성전자주식회사 | 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체 |
| CN106605228B (zh) | 2014-07-07 | 2019-08-16 | 耶达研究及发展有限公司 | 计算蛋白质设计的方法 |
| PH12017501792B1 (en) | 2015-04-02 | 2022-07-20 | Molecular Partners Ag | Recombinant binding proteins and their use |
| AU2017331329B2 (en) * | 2016-09-22 | 2020-10-29 | Molecular Partners Ag | Recombinant binding proteins and their use |
| CN109952376B (zh) | 2016-11-01 | 2023-09-05 | 箭头药业股份有限公司 | αvβ6整联蛋白配体及其应用 |
| US11127483B2 (en) | 2017-03-07 | 2021-09-21 | Igc Bio, Inc. | Computational pipeline for antibody modeling and design |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| WO2019180243A1 (en) | 2018-03-22 | 2019-09-26 | Charité-Universitätsmedizin Berlin | Crispr associated protein reactive t cell immunity |
| EP3807401A1 (en) | 2018-06-15 | 2021-04-21 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
| MX2021004012A (es) | 2018-10-08 | 2021-06-23 | Univ Zuerich | Polipeptidos tetramericos de union a her2. |
| US20220017433A1 (en) | 2018-11-21 | 2022-01-20 | Universität Zürich | Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction |
| EP3677911A3 (en) | 2019-01-03 | 2020-07-29 | Universität Basel | Use of non-agonist ligands for suppression of metastasis |
| WO2020144378A1 (en) | 2019-01-11 | 2020-07-16 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| EP3953712A1 (en) | 2019-04-10 | 2022-02-16 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
| JP7742309B2 (ja) * | 2019-06-04 | 2025-09-19 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 改善された安定性を有する設計されたアンキリン反復ドメイン |
| SG11202112925PA (en) * | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| AR119080A1 (es) | 2019-06-04 | 2021-11-24 | Molecular Partners Ag | Proteínas multiespecíficas |
| WO2021044050A1 (en) | 2019-09-05 | 2021-03-11 | Genome Biologics Ug | Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| CN114929730A (zh) | 2019-12-11 | 2022-08-19 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| WO2021122813A1 (en) | 2019-12-16 | 2021-06-24 | Universität Basel | Angiogenesis promoting agents for prevention of metastatic cancer |
| WO2021176008A1 (en) | 2020-03-04 | 2021-09-10 | Cornell University | Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer |
| WO2021204781A1 (en) | 2020-04-06 | 2021-10-14 | Universität Zürich | Artc1 ligands for cancer treatment |
| WO2021224686A1 (en) | 2020-05-06 | 2021-11-11 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses |
| JP2023528204A (ja) * | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| WO2021229076A1 (en) * | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| EP4153316A1 (en) | 2020-05-19 | 2023-03-29 | Boehringer Ingelheim International GmbH | Binding molecules for the treatment of cancer |
| WO2021239844A1 (en) | 2020-05-27 | 2021-12-02 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes |
| WO2021239999A1 (en) | 2020-05-28 | 2021-12-02 | Universität Zürich | Il-12 pd-l1 ligand fusion protein |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| KR20230048151A (ko) | 2020-08-18 | 2023-04-10 | 유니버시타트 취리히 | Cd25 편향된 항-il-2 항체 |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| CN114106194B (zh) * | 2020-08-31 | 2024-01-16 | 中国科学院天津工业生物技术研究所 | 一种用于治疗糖尿病和/或肥胖症的融合蛋白 |
| WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
| US20240052033A1 (en) | 2020-12-16 | 2024-02-15 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| WO2022130300A1 (en) | 2020-12-16 | 2022-06-23 | Molecular Partners Ag | Novel slow-release prodrugs |
| US20240310378A1 (en) | 2021-02-11 | 2024-09-19 | Universität Zürich | Use of markers found on lymph node metastatic samples for the prognosis of breast cancer |
| EP4043481A1 (en) * | 2021-02-15 | 2022-08-17 | Affilogic | Compounds and methods for extending half life of biomolecules |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| WO2022190018A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| KR20230155464A (ko) | 2021-03-09 | 2023-11-10 | 몰리큘라 파트너스 아게 | 신규한 DARPin-기반 다중특이성 T-세포 인게이저 |
| AU2022232216A1 (en) | 2021-03-09 | 2023-10-05 | Molecular Partners Ag | Protease cleavable prodrugs |
| WO2022219185A1 (en) | 2021-04-16 | 2022-10-20 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| IL310615A (en) | 2021-08-05 | 2024-04-01 | Immunos Therapeutics Ag | Pharmaceutical compositions comprising HLA fusion proteins |
| KR20240045260A (ko) | 2021-08-05 | 2024-04-05 | 이뮤노스 테라퓨틱스 아게 | Hla 융합 단백질을 포함하는 복합 치료제 |
| WO2023021006A1 (en) | 2021-08-16 | 2023-02-23 | Universität Zürich | Il-1 targeting agents for treatment of pitiyriasis rubra pilaris |
| WO2023021050A1 (en) | 2021-08-17 | 2023-02-23 | Athebio Ag | Variants of ankyrin repeat domains |
| EP4137508A1 (en) | 2021-08-17 | 2023-02-22 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023036849A1 (en) | 2021-09-07 | 2023-03-16 | ETH Zürich | Identifying and predicting future coronavirus variants |
| EP4163380A1 (en) | 2021-10-08 | 2023-04-12 | ETH Zurich | Device and method for manipulation of extracellular vesicles |
| WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| EP4260907A1 (en) | 2022-04-11 | 2023-10-18 | Universität Zürich | Agents for treatment of endometriosis and other benign gynecological neoplasms |
| WO2024002914A1 (en) | 2022-06-27 | 2024-01-04 | Charité-Universitätsmedizin Berlin | Prediction of, and composition to improve, tendon healing |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2023194628A2 (en) | 2022-08-16 | 2023-10-12 | Athebio Ag | Variants of ankyrin repeat domains |
| WO2024037743A1 (en) | 2022-08-16 | 2024-02-22 | Athebio Ag | Variants of ankyrin repeat domains |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024064200A2 (en) * | 2022-09-20 | 2024-03-28 | The Texas A&M University System | Darpin-containing compositions and methods thereof |
| WO2024133013A1 (en) | 2022-12-19 | 2024-06-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Means and methods to target endogenous condensates |
| EP4662230A1 (en) | 2023-02-08 | 2025-12-17 | ImmunOs Therapeutics AG | Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2025008519A1 (en) | 2023-07-05 | 2025-01-09 | Universität Bern | Il-1ra blockers for treatment and prevention of sepsis |
| WO2025021293A1 (en) | 2023-07-25 | 2025-01-30 | Universität Zürich | Disruption of rbr1 expression in plant cells |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025202503A1 (en) | 2024-03-28 | 2025-10-02 | Universität Zürich | Extracellular vesicles carrying cancer specific splice variants |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| DE69834032T2 (de) | 1997-04-23 | 2006-12-07 | Universität Zürich | Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren |
| HK1039355B (en) | 1998-12-02 | 2007-09-21 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| RU2299208C2 (ru) * | 2001-05-08 | 2007-05-20 | Шеринг Акциенгезельшафт | Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3 |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| ES2551682T3 (es) | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005097202A2 (en) | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| BRPI0613593A2 (pt) | 2005-07-08 | 2011-01-18 | Univ Zuerich | método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo |
| SI2402754T2 (sl) | 2006-03-06 | 2023-09-29 | Amunix Operating Inc. | Nestrukturirani rekombinantni polimeri in njihove uporabe |
| CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| JP2010505435A (ja) | 2006-10-11 | 2010-02-25 | アブリンクス エン．ヴェー． | 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用 |
| WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
| PL2173890T3 (pl) | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
| EP2190863B1 (en) | 2007-07-31 | 2015-09-02 | Affibody AB | New albumin binding compositions, methods and uses |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| US20110262964A1 (en) * | 2008-03-19 | 2011-10-27 | Hugues Bedouelle | Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use |
| CN102272148A (zh) * | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| TWI510246B (zh) * | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| WO2012060748A1 (en) * | 2010-11-03 | 2012-05-10 | Telefonaktiebolaget Lm Eriksson (Publ) | A radio base station and a method therein |
| DK2643349T3 (da) * | 2010-11-26 | 2019-11-25 | Molecular Partners Ag | Designede repeat-proteiner, der binder til serumalbumin |
| KR20140039203A (ko) * | 2011-04-29 | 2014-04-01 | 얀센 바이오테크 인코포레이티드 | Il4/il13 결합 반복 단백질 및 용도 |
| WO2014001442A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| PH12017501792B1 (en) * | 2015-04-02 | 2022-07-20 | Molecular Partners Ag | Recombinant binding proteins and their use |
-
2011
- 2011-11-25 DK DK11788815T patent/DK2643349T3/da active
- 2011-11-25 EP EP11788152.4A patent/EP2643348B1/en active Active
- 2011-11-25 ES ES11788815T patent/ES2758352T3/es active Active
- 2011-11-25 WO PCT/EP2011/071083 patent/WO2012069654A1/en not_active Ceased
- 2011-11-25 JP JP2013540387A patent/JP6173216B2/ja active Active
- 2011-11-25 PL PL11788815T patent/PL2643349T3/pl unknown
- 2011-11-25 CN CN201180066084.3A patent/CN103403024B/zh active Active
- 2011-11-25 RU RU2013128895A patent/RU2636552C2/ru active
- 2011-11-25 BR BR112013013043A patent/BR112013013043A2/pt not_active Application Discontinuation
- 2011-11-25 US US13/989,174 patent/US9284361B2/en active Active
- 2011-11-25 KR KR1020137014339A patent/KR20140032356A/ko not_active Ceased
- 2011-11-25 EP EP11788815.6A patent/EP2643349B1/en active Active
- 2011-11-25 CA CA2818990A patent/CA2818990C/en active Active
- 2011-11-25 CN CN202110301133.2A patent/CN113278077A/zh active Pending
- 2011-11-25 KR KR1020177010815A patent/KR101838037B1/ko active Active
- 2011-11-25 CA CA2818969A patent/CA2818969C/en active Active
- 2011-11-25 US US13/989,181 patent/US9221892B2/en active Active
- 2011-11-25 BR BR112013012786-4A patent/BR112013012786B1/pt active IP Right Grant
- 2011-11-25 WO PCT/EP2011/071084 patent/WO2012069655A2/en not_active Ceased
- 2011-11-25 RU RU2013128896A patent/RU2625882C2/ru active
- 2011-11-25 JP JP2013540386A patent/JP6105479B2/ja active Active
- 2011-11-25 BR BR122020011428-2A patent/BR122020011428B1/pt active IP Right Grant
- 2011-11-25 ES ES19160342T patent/ES2981441T3/es active Active
- 2011-11-25 EP EP19160342.2A patent/EP3514169B1/en active Active
- 2011-11-25 CN CN201180066086.2A patent/CN103459415B/zh active Active
- 2011-11-25 KR KR1020137014067A patent/KR101782790B1/ko active Active
- 2011-11-25 AU AU2011333665A patent/AU2011333665B2/en active Active
- 2011-11-25 AU AU2011333666A patent/AU2011333666B2/en active Active
-
2015
- 2015-11-20 US US14/947,148 patent/US9717802B2/en active Active
-
2016
- 2016-02-02 US US15/013,092 patent/US9775912B2/en active Active
- 2016-10-28 JP JP2016211658A patent/JP2017048216A/ja active Pending
-
2017
- 2017-06-23 US US15/631,028 patent/US10322190B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| HK1200842A1 (en) | Proteins with improved half-life and other properties | |
| IN2014CN00414A (enExample) | ||
| EP4276180A3 (en) | Clostridium histolyticum enzyme | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| WO2009130198A3 (en) | Hyperglycosylated human coagulation factor ix | |
| WO2012158965A3 (en) | Improved peptide pharmaceuticals for insulin resistance | |
| PH12019500596B1 (en) | Recombinant binding proteins and their use | |
| WO2007112940A3 (en) | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same | |
| WO2008033413A3 (en) | Albumin fusion proteins | |
| WO2007146038A3 (en) | Albumin fusion proteins | |
| EP3670536A3 (en) | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof | |
| EP4509189A3 (en) | Anti-fcrn antibodies | |
| MY177065A (en) | 4-1bb binding molecules | |
| EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| WO2012168431A3 (en) | Polypeptides | |
| NZ593641A (en) | Extended soluble ph20 polypeptides and uses thereof | |
| WO2009147248A3 (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
| TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
| HK1206638A1 (zh) | 用於生产化妆品蛋白质和肽的修饰的多核苷酸 | |
| WO2012158962A3 (en) | Improved peptide pharmaceuticals | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| EP3210625A3 (en) | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) | |
| UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140922 |